- Applied DNA Sciences' ( NASDAQ: APDN ) said on Monday that animal data showed that a linearDNA vaccine successfully elicited neutralizing antibodies and cellular immunity against COVID-19.
- The positive data showing safety and immunogenicity of a linDNA vaccine candidate against SARS-CoV-2 was in a cohort of family-owned cats.
- The vaccine will be used in upcoming in vivo animal studies to assess the performance of linDNA-LNP vaccines and will inform the final design of the Company’s lead veterinary asset, a linDNA-LNP canine lymphoma vaccine candidate.
- The manuscript, "A Linear DNA Vaccine Candidate Encoding the SARS-CoV-2 Receptor Binding Domain Elicits Protective Immunity in Domestic Cats," is available in preprint on bioRxiv and will be submitted for peer-reviewed publication, the company said.
For further details see:
Applied DNA announces positive data from veterinary vaccine trial to treat COVID-19